NeoPhore

Executive Summary

NeoPhore is a UK-based biotechnology company founded in 2017, pioneering a novel approach to cancer immunotherapy by targeting the DNA Mismatch Repair (MMR) pathway. The company develops first-in-class small molecule inhibitors that transiently block MMR in MMR-proficient tumors, converting them to an MMR-deficient state. This conversion sensitizes tumors to immune checkpoint inhibitors, potentially expanding the patient population that can achieve durable responses from immunotherapy. NeoPhore's strategy addresses a critical unmet need, as MMR-deficient tumors are known to respond well to checkpoint inhibitors, but only about 15% of colorectal and other cancers are naturally MMR-deficient. By pharmacologically inducing this phenotype, NeoPhore aims to make immunotherapy effective for the majority of patients with MMR-proficient tumors, a significantly larger market opportunity.

Upcoming Catalysts (preview)

• Q2 2026Presentation of preclinical proof-of-concept data at major oncology conference70% success
• Q4 2026Filing of Investigational New Drug (IND) application or Clinical Trial Application (CTA)40% success
• Q1 2027Initiation of first-in-human Phase 1 clinical trial30% success